Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
Jackson
J D
JD
Outcomes Research, Bristol-Myers Squibb, Princeton, NJ 08543, USA.
D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D017850:Economics, Pharmaceutical; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000191:economics* / Q000627:therapeutic use; D014481:United States
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents